IN8BIO, Inc. (INAB): Operating Income

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$19.44M

Year ended 2025-12-31

-$18.67M

Trailing 12 months to 2026-06-30

2020-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$19.44M	n/m	2026-03-12, From 2025-01-01
2024-12-31	-$30.44M	n/m	2026-03-12, From 2024-01-01
2023-12-31	-$30.01M	n/c	2025-03-13, From 2023-01-01
2022-12-31	-$28.52M	n/m	2024-03-14, From 2022-01-01
2021-12-31	-$14.65M	n/m	2023-03-30, From 2021-01-01
2020-12-31	-$8.56M	n/a	2022-03-17, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
IN8BIO, Inc. (INAB)	2025-12-31	-$19.44M	n/m
Inmune Bio, Inc. (INMB)	2025-12-31	-$47.38M	n/m
Jasper Therapeutics, Inc. (JSPR)	2025-12-31	-$83.88M	n/m
CEL SCI Corp (CVM)	2025-09-30	-$24.81M	n/m
Windtree Therapeutics Inc (WINT)	2024-12-31	-$26.14M	n/m
Champions Oncology, Inc. (CSBR)	2026-04-30	-$1.14M	n/m
Pluri Inc. (PLUR)	2026-06-30	-$24.94M	n/m
Viskase Holdings, Inc. (VISK)	2025-12-31	-$5.31M	n/m
Ocugen, Inc. (OCGN)	2025-12-31	-$62.92M	n/m

Compare INAB, INMB, JSPR, CVM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗